103 related articles for article (PubMed ID: 20357746)
21. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta.
Kim F; Tysseling KA; Rice J; Pham M; Haji L; Gallis BM; Baas AS; Paramsothy P; Giachelli CM; Corson MA; Raines EW
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):989-94. PubMed ID: 15731493
[TBL] [Abstract][Full Text] [Related]
22. [Short- and long-term effects of the new oral prostacyclin analogue, beraprost sodium, in patients with severe pulmonary hypertension].
Saji T; Ozawa Y; Nakayama T; Matsuura H; Hashiguchi R; Matsuo N; Muto H; Yamazaki J; Morishita T; Saito T
J Cardiol; 1996 Apr; 27(4):197-205. PubMed ID: 8642506
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacological and clinical properties of beraprost sodium, orally active prostacyclin analogue].
Nishio S; Kurumatani H
Nihon Yakurigaku Zasshi; 2001 Feb; 117(2):123-30. PubMed ID: 11233303
[TBL] [Abstract][Full Text] [Related]
24. Beraprost sodium regulates cell cycle in vascular smooth muscle cells through cAMP signaling by preventing down-regulation of p27(Kip1).
Ii M; Hoshiga M; Fukui R; Negoro N; Nakakoji T; Nishiguchi F; Kohbayashi E; Ishihara T; Hanafusa T
Cardiovasc Res; 2001 Dec; 52(3):500-8. PubMed ID: 11738067
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
Otsuki M; Goya K; Kasayama S
Vasc Health Risk Manag; 2005; 1(3):209-15. PubMed ID: 17319106
[TBL] [Abstract][Full Text] [Related]
26. Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension.
Miyata M; Ueno Y; Sekine H; Ito O; Sakuma F; Koike H; Nishio S; Nishimaki T; Kasukawa R
J Cardiovasc Pharmacol; 1996 Jan; 27(1):20-6. PubMed ID: 8656653
[TBL] [Abstract][Full Text] [Related]
27. [Effect of long-term therapy with oral Beraprost on survival of patients with arterial and inoperable thromboembolic pulmonary hypertension].
Kurzyna M; Florczyk M; Fijałkowska A; Kuca P; Szewczyk G; Burakowski J; Kober J; Sikora J; Wawrzyńska L; Szturmowicz M; Tomkowskil W; Torbicki A
Pol Arch Med Wewn; 2004 Apr; 111(4):477-82. PubMed ID: 15517762
[TBL] [Abstract][Full Text] [Related]
28. Inhibition by beraprost sodium of thrombin-induced increase in endothelial macromolecular permeability.
Imai-Sasaki R; Kainoh M; Ogawa Y; Ohmori E; Asai Y; Nakadate T
Prostaglandins Leukot Essent Fatty Acids; 1995 Aug; 53(2):103-8. PubMed ID: 7480071
[TBL] [Abstract][Full Text] [Related]
29. Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels.
Li S; Wang Y; Chen L; Wang Z; Liu G; Zuo B; Liu C; Sun D
J Mol Med (Berl); 2019 Jun; 97(6):777-791. PubMed ID: 30923844
[TBL] [Abstract][Full Text] [Related]
30. Prostacyclin signaling boosts NADPH oxidase 4 in the endothelium promoting cytoprotection and angiogenesis.
Peshavariya HM; Liu GS; Chang CW; Jiang F; Chan EC; Dusting GJ
Antioxid Redox Signal; 2014 Jun; 20(17):2710-25. PubMed ID: 24450852
[TBL] [Abstract][Full Text] [Related]
31. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.
Melian EB; Goa KL
Drugs; 2002; 62(1):107-33. PubMed ID: 11790158
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory Effects of Beraprost Sodium in Murine Hepatic Sinusoidal Obstruction Syndrome.
Nakura M; Miyashita T; Yamamoto Y; Takada S; Kanou S; Tajima H; Takamura H; Ohta T
Anticancer Res; 2020 Sep; 40(9):5171-5180. PubMed ID: 32878805
[TBL] [Abstract][Full Text] [Related]
33. PPARdelta-mediated p21/p27 induction via increased CREB-binding protein nuclear translocation in beraprost-induced antiproliferation of murine aortic smooth muscle cells.
Sue YM; Chung CP; Lin H; Chou Y; Jen CY; Li HF; Chang CC; Juan SH
Am J Physiol Cell Physiol; 2009 Aug; 297(2):C321-9. PubMed ID: 19587222
[TBL] [Abstract][Full Text] [Related]
34. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension.
Saji T; Ozawa Y; Ishikita T; Matsuura H; Matsuo N
Am J Cardiol; 1996 Jul; 78(2):244-7. PubMed ID: 8712155
[TBL] [Abstract][Full Text] [Related]
35. Beraprost sodium attenuates cigarette smoke extract-induced apoptosis in vascular endothelial cells.
Chen Y; Luo H; Kang N; Guan C; Long Y; Cao J; Shen Q; Li J; Yang M; Peng H; Chen P
Mol Biol Rep; 2012 Dec; 39(12):10447-57. PubMed ID: 23053949
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers.
Demolis JL; Robert A; Mouren M; Funck-Brentano C; Jaillon P
J Cardiovasc Pharmacol; 1993 Nov; 22(5):711-6. PubMed ID: 7506323
[TBL] [Abstract][Full Text] [Related]
37. Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction.
Ono F; Nagaya N; Okumura H; Shimizu Y; Kyotani S; Nakanishi N; Miyatake K
Chest; 2003 May; 123(5):1583-8. PubMed ID: 12740277
[TBL] [Abstract][Full Text] [Related]
38. Effect of long-term administration of a prostacyclin analogue (beraprost sodium) on myocardial fibrosis in Dahl rats.
Kaneshige T; Saida Y; Tanaka R; Soda A; Fukushima A; Ida N; Takenaka M; Yamane Y
J Vet Med Sci; 2007 Dec; 69(12):1271-6. PubMed ID: 18176024
[TBL] [Abstract][Full Text] [Related]
39. Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions.
Schwartz BG; Jackson G; Stecher VJ; Campoli-Richards DM; Kloner RA
Am J Med; 2013 Mar; 126(3):192-9. PubMed ID: 23410557
[TBL] [Abstract][Full Text] [Related]
40. Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects.
Warot D; Berlin I; Aymard G; Ankri A; Fabry C; Besse B; Lechat P; Diquet B
Fundam Clin Pharmacol; 2000; 14(3):231-6. PubMed ID: 15602800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
